Agios Pharmaceuticals (AGIO) Expected to Announce Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) is anticipated to release its Q4 2024 earnings data before the market opens on Thursday, February 20th. Analysts expect Agios Pharmaceuticals to post earnings of ($1.69) per share and revenue of $9.35 million for the quarter. Parties interested in participating in the company's conference call can do so using this link.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 2,051.38% and a negative return on equity of 2.93%. On average, analysts expect Agios Pharmaceuticals to post $0 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO traded down $0.08 during mid-day trading on Friday, hitting $33.22. The company's stock had a trading volume of 786,683 shares, compared to its average volume of 609,544. Agios Pharmaceuticals has a 52-week low of $24.88 and a 52-week high of $62.58. The stock's fifty day simple moving average is $35.19 and its two-hundred day simple moving average is $43.36. The firm has a market capitalization of $1.89 billion, a P/E ratio of 2.92 and a beta of 0.88.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.93% of the company's stock.

Analysts Set New Price Targets

AGIO has been the topic of several research reports. Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. StockNews.com downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of "Hold" and a consensus target price of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.